The Inhale project is assessing respiratory disease tests on Oxford Nanopore's MinIon and PCR platforms from Curetis and BioMérieux's BioFire Diagnostics.
BioMérieux said that the FilmArray RP2 reduces sample-to-result time to 45 minutes from about one hour, and provides increased pathogen coverage and sensitivity.
Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.
Companies with diverse infectious disease diagnostic technology offerings said that molecular methods are complementary to, not competitive with traditional diagnostics.
The firm's GI panel has also been recently evaluated in pediatric populations, demonstrating a marked increase in overall pathogen detection.
The firm also reported a 46 percent increase in molecular biology sales due to growth in its FilmArray line.
The test detects 11 viruses and three bacterial pathogens in approximately one hour and requires two minutes of hands-on time.
The study involved 11 sites and 1,560 prospectively collected patient samples and demonstrated high overall positive and negative percent agreement with comparator assays.
ISS astronauts will soon begin testing the Oxford Nanopore MinIon and two PCR platforms while researchers on Earth continue to evaluate microarrays for use in space.
On an organic basis, Q1 revenues grew more than 11 percent, driven in part by strong sales of its FilmArray, Vidas, and Vitek product portfolios.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.